Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pembrolizumab benefits some patients with advanced cervical cancer

Publish date:: April 9, 2019

Key clinical point: Pembrolizumab is a reasonable option for patients with advanced cervical cancer, especially those positive for PD-L1.

Major finding: Three PD-L1 patients had a complete response and nine had a partial response.

Study details: The prospective open-label study comprised 98 subjects.

Disclosures: Merck & Co. sponsored the study.

Citation:

Chung HC et al. J Clin Oncol. 2019 April 3. doi: 10.1200/JCO.18.01265.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,